Opdualag Nivolumab Relatlimab LAG3 Inhibitor Melanoma Review 2026
Author: Critical Kare PharmaImmuno-Oncology Desk
On October 16, 2026, melanoma and immuno-oncology symposiums highlighted Opdualag® (Nivolumab and Relatlimab-rmbw 480 mg / 160 mg fixed-dose vial) by Bristol Myers Squibb as the first approved anti-LAG-3 combination immunotherapy.
Combining the anti-PD-1 antibody nivolumab with the novel anti-LAG-3 antibody relatlimab in a single fixed-dose infusion, Opdualag revitalizes exhausted T-cells via non-redundant inhibitory pathways, significantly outperforming nivolumab monotherapy in frontline advanced melanoma.
Through Critical Kare Pharma, original manufacturer supplies of Opdualag Nivolumab + Relatlimab Infusion Vials are provided to oncology clinics globally under strict 2°C–8°C cold-chain controls.
The RELATIVITY-047 Phase 3 Clinical Outcomes
- Progression-Free Survival Doubling: Doubled median progression-free survival compared to nivolumab monotherapy (10.1 months vs. 4.6 months; hazard ratio 0.75).
- Favorable Safety Profile: Grade 3/4 treatment-related adverse event rate of 18.9%, markedly lower than historical anti-CTLA-4 plus anti-PD-1 combinations (~55%).
- Dosing: Single fixed-dose vial containing 480 mg nivolumab and 160 mg relatlimab administered intravenously every 4 weeks over 60 minutes.
Global Named-Patient Sourcing
Coordinated under US FDA Personal Importation, UK MHRA Special Import, and ANVISA corridors with verified batch Certificates of Analysis.
